Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP6 | P55212 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | HCAR3 | P49019 | 13/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | APEX1 | P27695 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3855174 | 0.83 | CASP6 (0.64) | CASP6TSHRHCAR3LMNAAPEX1 | |
| SCHEMBL29886656 | 0.77 | CASP6 (0.64) | CASP6TSHRHCAR3LMNAAPEX1 | |
| SCHEMBL1265098 | 0.77 | CASP6 (0.64) | CASP6TSHRHCAR3LMNAAPEX1 | |
| SCHEMBL20690493 | 0.74 | CASP6 (0.64) | CASP6TSHRHCAR3LMNAAPEX1 | |
| SCHEMBL2292095 | 0.74 | CASP6 (0.64) | CASP6TSHRHCAR3LMNAAPEX1 | |
| SCHEMBL31615734 | 0.74 | CASP6 (0.58) | CASP6TSHRHCAR3LMNA | |
| 4-Chloro-3-Nitrobenzoic Acid SCHEMBL10608947 | 0.73 | VCAM1 (0.74) | CASP6TSHRHCAR3LMNA | |
| SCHEMBL8131816 | 0.73 | CASP6 (0.54) | CASP6TSHRHCAR3LMNAAPEX1 | |
| SCHEMBL27719472 | 0.73 | TSHR (0.50) | CASP6TSHRHCAR3LMNAPOLB | |
| SCHEMBL504055 | 0.72 | CASP6 (1.00) | CASP6TSHRHCAR3LMNAAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6812226-B2 | FOR THERAPY OF RHEUMATOID ARTHRITIS, EFFECTING IMMUNOSUPPRESSION | ASTRAZENECA AB (SE) | 2004-11-02 | — | — | US | disclosed |
| EP-1242396-B1 | NEW P2X 7 RECEPTOR ANTAGONISTS FOR USE IN THE TREATMENT OF INFLAMMATORY, IMMUNE OR CARDIOVASCULAR DISEASES | ASTRAZENECA AB (SE) | 2003-09-24 | — | — | EP | disclosed |
| US-20030040513-A1 | P2x7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases | ASTRAZENECA AB (SE) | 2003-02-27 | — | — | US | disclosed |
| EP-1242396-A1 | NEW P2X 7 RECEPTOR ANTAGONISTS FOR USE IN THE TREATMENT OF INFLAMMATORY, IMMUNE OR CARDIOVASCULAR DISEASES | AstraZeneca AB (SE) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001044213-A1 | NEW P2X7 RECEPTOR ANTAGONISTS FOR USE IN THE TREATMENT OF INFLAMMATORY, IMMUNE OR CARDIOVASCULAR DISEASES | ASTRAZENECA AB (SE) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040513-A1 | P2x7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases | P2RX1, P2RX2, P2RX3 | CASP6 1945/4885TSHR 690/4885HCAR3 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.